June 22, 2023 07:39 AM EDTUpdated 02:37 PM
Cell/Gene Tx
FDA+

Sarep­ta's gene ther­a­py for Duchenne ex­pect­ed to get FDA rul­ing to­day

Jaimy Lee

Deputy Editor

Up­date: On Thurs­day af­ter­noon, the FDA grant­ed ac­cel­er­at­ed ap­proval to Sarep­ta’s gene ther­a­py. To read the full sto­ry, click here.

Sarep­ta Ther­a­peu­tics is set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times